HSANZ: Myeloma
Tracks
HSANZ
Wednesday, November 8, 2023 |
9:00 AM - 10:30 AM |
Plenary 3 |
Details
Kindly sponsored by Amgen
Speaker
Dr Georgia McCaughan
Consultant Haematologist
St Vincent's Hospital
Sequencing therapies for relapsed myeloma in the Australian setting
9:00 AM - 9:30 AMBiography
Georgia McCaughan is a Consultant Clinical and Laboratory Haematologist at St Vincent's Hospital, Sydney, and a Senior Research Associate at the Garvan Institute of Medical Research. She has a clinical and research interest in plasma cell dyscrasias including multiple myeloma and AL amyloidosis. She is passionate about increasing patient access to clinical trials and is involved in novel clinical trial design through the Australian Leukaemia and Lymphoma Myeloma Working Group and is also on the steering committee of the Australian Myeloma Research Consortium. Her translational research work at the Garvan Institute of Medical Research is focused on cancer cell dormancy and myeloma bone disease.
Dr Christian Bryant
Haematologist
Royal Prince Alfred Hospital
MRD monitoring in myeloma
9:30 AM - 10:00 AMBiography
Dr Christian Bryant BSc(Med) MBBS PhD FRACP FRCAP, is a Consultant Haematologist at the Institute of Haematology, Royal Prince Alfred Hospital, Sydney NSW, and a Senior Lecturer in Medicine at The University of Sydney.
After completing a PhD in immunology in 2017, Dr Bryant returned to the clinic to focus on Multiple Myeloma and stem cell transplantation. He continues his laboratory studies at the Royal Prince Alfred Myeloma Research Laboratory working to understand how T cell immunity contributes to the disease process in Myeloma and develop strategies to target MRD and improve patient outcomes.
Dr Georgia McCaughan
Consultant Haematologist
St Vincent's Hospital
Amyloidosis
10:00 AM - 10:30 AMBiography
Georgia McCaughan is a Consultant Clinical and Laboratory Haematologist at St Vincent's Hospital, Sydney, and a Senior Research Associate at the Garvan Institute of Medical Research. She has a clinical and research interest in plasma cell dyscrasias including multiple myeloma and AL amyloidosis. She is passionate about increasing patient access to clinical trials and is involved in novel clinical trial design through the Australian Leukaemia and Lymphoma Myeloma Working Group and is also on the steering committee of the Australian Myeloma Research Consortium. Her translational research work at the Garvan Institute of Medical Research is focused on cancer cell dormancy and myeloma bone disease.
Chairperson
P Joy Ho
Haematologist
Royal Prince Alfred Hospital
Anna Kalff
![loading](/Content/Images/loader-large.gif)